According to a recent LinkedIn post from Click Therapeutics Inc, the journal npj Digital Medicine has published a manuscript analyzing two randomized controlled Phase III trials of CT-132, its FDA-authorized prescription digital therapeutic for episodic migraine prevention. The integrated post-hoc analysis of the ReMMi-D and ReMMiD-C studies, covering 678 patients, is described as showing significant reductions in monthly migraine days, along with improvements in migraine disability and quality-of-life metrics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post further notes that the adjunctive benefits of CT-132 were observed across patients using a range of migraine medications, including CGRP inhibitors, and that no device-related adverse events were reported in the analysis. For investors, peer-reviewed publication of positive late-stage clinical data could strengthen the therapeutic’s credibility with clinicians and payers, potentially supporting broader adoption and reimbursement, while also reinforcing Click Therapeutics’ position in the emerging prescription digital therapeutics segment.
The emphasis on safety and compatibility with existing pharmacologic treatments may position CT-132 as an add-on option rather than a replacement, which can ease integration into current care pathways and expand its addressable market. If these clinical and real-world benefits translate into increased prescription volumes and favorable coverage decisions, Click Therapeutics could see enhanced revenue prospects and a stronger competitive foothold against other digital and traditional migraine therapies.